274 related articles for article (PubMed ID: 18391047)
1. Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile.
Hinkson PL; Dinardo C; DeCiero D; Klinger JD; Barker RH
Antimicrob Agents Chemother; 2008 Jun; 52(6):2190-5. PubMed ID: 18391047
[TBL] [Abstract][Full Text] [Related]
2. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.
Louie TJ; Peppe J; Watt CK; Johnson D; Mohammed R; Dow G; Weiss K; Simon S; John JF; Garber G; Chasan-Taber S; Davidson DM;
Clin Infect Dis; 2006 Aug; 43(4):411-20. PubMed ID: 16838228
[TBL] [Abstract][Full Text] [Related]
3. Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection.
Baines SD; Freeman J; Wilcox MH
Antimicrob Agents Chemother; 2009 May; 53(5):2202-4. PubMed ID: 19223641
[TBL] [Abstract][Full Text] [Related]
4. Human intestinal enteroids as a model of
Engevik MA; Danhof HA; Chang-Graham AL; Spinler JK; Engevik KA; Herrmann B; Endres BT; Garey KW; Hyser JM; Britton RA; Versalovic J
Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G870-G888. PubMed ID: 32223302
[No Abstract] [Full Text] [Related]
5. Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.
Hussack G; Tanha J
Toxins (Basel); 2010 May; 2(5):998-1018. PubMed ID: 22069622
[TBL] [Abstract][Full Text] [Related]
6. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure.
Hirota SA; Iablokov V; Tulk SE; Schenck LP; Becker H; Nguyen J; Al Bashir S; Dingle TC; Laing A; Liu J; Li Y; Bolstad J; Mulvey GL; Armstrong GD; MacNaughton WK; Muruve DA; MacDonald JA; Beck PL
Infect Immun; 2012 Dec; 80(12):4474-84. PubMed ID: 23045481
[TBL] [Abstract][Full Text] [Related]
7. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.
Wang H; Sun X; Zhang Y; Li S; Chen K; Shi L; Nie W; Kumar R; Tzipori S; Wang J; Savidge T; Feng H
Infect Immun; 2012 Aug; 80(8):2678-88. PubMed ID: 22615245
[TBL] [Abstract][Full Text] [Related]
8. Human peptide α-defensin-1 interferes with Clostridioides difficile toxins TcdA, TcdB, and CDT.
Fischer S; Ückert AK; Landenberger M; Papatheodorou P; Hoffmann-Richter C; Mittler AK; Ziener U; Hägele M; Schwan C; Müller M; Kleger A; Benz R; Popoff MR; Aktories K; Barth H
FASEB J; 2020 May; 34(5):6244-6261. PubMed ID: 32190927
[TBL] [Abstract][Full Text] [Related]
9. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer.
Weiss K
Int J Antimicrob Agents; 2009 Jan; 33(1):4-7. PubMed ID: 18804351
[TBL] [Abstract][Full Text] [Related]
10. Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease.
Sambol SP; Merrigan MM; Lyerly D; Gerding DN; Johnson S
Infect Immun; 2000 Oct; 68(10):5480-7. PubMed ID: 10992443
[TBL] [Abstract][Full Text] [Related]
11. Development and optimization of a novel assay to measure neutralizing antibodies against Clostridium difficile toxins.
Xie J; Zorman J; Indrawati L; Horton M; Soring K; Antonello JM; Zhang Y; Secore S; Miezeiewski M; Wang S; Kanavage AD; Skinner JM; Rogers I; Bodmer JL; Heinrichs JH
Clin Vaccine Immunol; 2013 Apr; 20(4):517-25. PubMed ID: 23389929
[TBL] [Abstract][Full Text] [Related]
12. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.
Yang Z; Schmidt D; Liu W; Li S; Shi L; Sheng J; Chen K; Yu H; Tremblay JM; Chen X; Piepenbrink KH; Sundberg EJ; Kelly CP; Bai G; Shoemaker CB; Feng H
J Infect Dis; 2014 Sep; 210(6):964-72. PubMed ID: 24683195
[TBL] [Abstract][Full Text] [Related]
13. Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.
Maynard-Smith M; Ahern H; McGlashan J; Nugent P; Ling R; Denton H; Coxon R; Landon J; Roberts A; Shone C
Vaccine; 2014 Feb; 32(6):700-5. PubMed ID: 24342251
[TBL] [Abstract][Full Text] [Related]
14. The role of purified Clostridium difficile glucosylating toxins in disease pathogenesis utilizing a murine cecum injection model.
Zhang Y; Yang Z; Gao S; Hamza T; Yfantis HG; Lipsky M; Feng H
Anaerobe; 2017 Dec; 48():249-256. PubMed ID: 29031928
[TBL] [Abstract][Full Text] [Related]
15. Development and evaluation of a PCR method for detection of the Clostridium difficile toxin B gene in stool specimens.
Guilbault C; Labbé AC; Poirier L; Busque L; Béliveau C; Laverdière M
J Clin Microbiol; 2002 Jun; 40(6):2288-90. PubMed ID: 12037113
[TBL] [Abstract][Full Text] [Related]
16. Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity.
Romano MR; Leuzzi R; Cappelletti E; Tontini M; Nilo A; Proietti D; Berti F; Costantino P; Adamo R; Scarselli M
Toxins (Basel); 2014 Apr; 6(4):1385-96. PubMed ID: 24759173
[TBL] [Abstract][Full Text] [Related]
17. Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea.
Scheinfeld N; Biggers K
Curr Opin Investig Drugs; 2008 Aug; 9(8):913-24. PubMed ID: 18666039
[TBL] [Abstract][Full Text] [Related]
18. The roles of toxin A and toxin B in Clostridium difficile infection: insights from the gnotobiotic piglet model.
Steele J; Parry N; Tzipori S
Gut Microbes; 2014; 5(1):53-7. PubMed ID: 24394234
[TBL] [Abstract][Full Text] [Related]
19. The Importance of Therapeutically Targeting the Binary Toxin from
Abeyawardhane DL; Godoy-Ruiz R; Adipietro KA; Varney KM; Rustandi RR; Pozharski E; Weber DJ
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805767
[TBL] [Abstract][Full Text] [Related]
20. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
